This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
HomeSearch

Menu

Close

SerotypesSerotypesSerotype CoverageSerotype SelectionCase CoverageEfficacyEfficacyInvasive Pneumococcal DiseaseOtitis MediaClinical Trial Results

Clinical Trial
Results

Study DesignImmunogenicitySafety ProfileDosing & Recommendations

Dosing &
Recommendations

DosingAdherenceDisease BurdenDisease BurdenDisease BurdenDisparitiesAccess & SupportAccess &
SupportOrder Prevnar 20®Commercial health plansEventsMaterialsVideosGeneral Inquiries
Prescribing InformationPatient InformationIndications Patient Site
Prevnar 20®, the only pneumococcal vaccine option you need for children, is recommended as a 4-dose series for new PCV starts1*†‡§Complete all 4 doses on time to optimize the Prevnar 20 immune response2
  • Midseries transition: Prevnar 20 is a recommended option for transition from PCV15 for children aged 2 to 23 months1
  • Completion of missed doses: Prevnar 20 is recommended for completion of missed PCV doses for children aged 24 to 59 months1
 ACIP recommends Prevnar 20 as a PCV option for children under 2 years old and for eligible children 2 to 18 years old with certain risk conditions.1¶

Children who have received a complete pneumococcal vaccine series that included Prevnar 20 do not need any additional doses.1

ReferencesACIP=Advisory Committee on Immunization Practices; PCV=pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.
*Children who have received Prevnar 20 and who have certain underlying medical conditions do not require a dose of PPSV23.1
†The first dose may be given as early as 6 weeks of age.2
‡The recommended dosing interval for the first, second, and third doses is 4 to 8 weeks.2
§The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.2
Risk conditions include cerebrospinal fluid leak, chronic heart disease, chronic kidney disease, chronic liver disease, chronic lung disease (including moderate persistent or severe persistent asthma), cochlear implant, diabetes mellitus, and immunocompromising conditions.1Prevnar 20 is the only pneumococcal vaccine option you need for children with certain underlying medical conditions that increase the risk of pneumococcal disease1* Choose vaccination status:

Fully vaccinated with
another PCV 

Unvaccinated

Incomplete

Tab Number 4

Tab Number 5

Aged 2 to 18 years with risk conditions*

Additional dose recommended:
1 dose of Prevnar 20, given at least 8 weeks after last PCV dose

No additional doses needed if Prevnar 20 was part of the 4-dose schedule.

Aged 6 to 18 years with risk conditions*

Additional dose recommended:
1 dose of Prevnar 20

No previous PCV13, PCV15, or PCV20 vaccination.1

Aged 24 to 71 months with risk conditions*



Additional doses recommended:

Any incomplete schedule and <3 PCV doses by 24 months of age=2 doses of Prevnar 20

3 PCV doses all at <12 months of age=1 dose of Prevnar 20

Given at least 8 weeks after last PCV dose.

Children who have received a complete pneumococcal vaccine series that included Prevnar 20 do not need any additional doses.1Only Prevnar 20 eliminates the need for one or more 23-valent pneumococcal polysaccharide vaccines in children with certain underlying medical conditions.1*Certain underlying medical conditions increase the risk of invasive pneumococcal disease (IPD)3*

More than 1.2 million children who have asthma could have up to a 2.1x greater risk of IPD than healthy children3†

Children aged 5 to 17 years with diabetes have an up to 5.4x greater risk of IPD than healthy children3

More than 135,000 children who have chronic heart disease could have 2.4x to 9.9x greater risk of IPD than healthy children3

Some studies show that people with sickle cell disease have up to 40x greater risk of IPD than healthy children and young adults4

Prevnar 20 ACIP Recommendation
The ACIP has voted unanimously to recommend Prevnar 20 as an option for pneumococcal conjugate vaccination for children under 2 years of age and for eligible children aged 2 to 18 years with certain underlying conditions that increase the risk of pneumococcal disease.1*

 Complete all 4 doses to optimize the Prevnar 20 immune response2
See post-dose 4 Prevnar 20 antibody levels
LoadingDosing & Recommendations Stock Prevnar 20 for your patients

To stock Prevnar 20, call 1-800-
666-7248 or click below to order on Pfizer Prime.

 Order todayACIP=Advisory Committee on Immunization Practices; PCV=pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine.
*Risk conditions include cerebrospinal fluid leak, chronic heart disease, chronic kidney disease, chronic liver disease, chronic lung disease (including moderate persistent or severe persistent asthma), cochlear implant, diabetes mellitus, and immunocompromising conditions.1
†The Centers for Disease Control and Prevention recommends Prevnar 20 in patients with underlying medical conditions, including moderate to severe asthma.1References:Farrar JL, Gierke R, Andrejko KL, et al. Use of 20-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072.Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59(5):615-623. Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI; Members of the Massachusetts Department of Public Health. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease. Pediatrics. 2015;135(3):495-503.
Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-2905 © 2025 Pfizer Inc.
All rights reserved. June 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2905
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
INDICATIONS 
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups, and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and risks
  • In individuals 2, 4, 6, and 12 through 15 months of age vaccinated with a 4-dose schedule, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, decreased appetite, injection site redness, injection site swelling, and fever
  • In individuals 15 months through 17 years of age vaccinated with a single dose, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, fatigue and muscle pain, decreased appetite, injection site swelling and redness, headache, and fever
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.INDICATIONSIndications
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age